1832 Asset Management
CPRX

1832 Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

1832 Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-225,800
Closed -$4.49M – 674
2024
Q3 		$4.49M Buy
+225,800
New +$4.19M ﹤0.01% 411

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

1832 Asset Management's CPRX Position: Q4 2024 in Review

1832 Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 225,800 shares — an estimated $4.49M sold.

1832 Asset Management first reported a position in CPRX in Q3 2024 and held it in 1 quarter. The position peaked at $4.49M in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • 1832 Asset Management reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • 1832 Asset Management sold 225,800 Catalyst Pharmaceutical shares in Q4 2024, an estimated $4.49M.
  • 1832 Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • 1832 Asset Management's Catalyst Pharmaceutical position peaked at $4.49M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on 1832 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.